Hikma Pharmaceuticals PLCShs Aktie 2324471 / GB00B0LCW083
26.60
EUR
0.20
EUR
0.76%
21:43:14
BMN
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Hikma Pharmaceuticals Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2024 | Hikma Pharmaceuticals PLCShs | 3.16 | 0.63 | GBP |
| 2023 | Hikma Pharmaceuticals PLCShs | 3.17 | 0.57 | GBP |
| 2022 | Hikma Pharmaceuticals PLCShs | 2.92 | 0.45 | GBP |
| 2021 | Hikma Pharmaceuticals PLCShs | 1.83 | 0.41 | GBP |
| 2020 | Hikma Pharmaceuticals PLCShs | 1.45 | 0.37 | GBP |
| 2019 | Hikma Pharmaceuticals PLCShs | 1.87 | 0.37 | GBP |
| 2018 | Hikma Pharmaceuticals PLCShs | 1.70 | 0.29 | GBP |
| 2017 | Hikma Pharmaceuticals PLCShs | 2.21 | 0.25 | GBP |
| 2016 | Hikma Pharmaceuticals PLCShs | 1.37 | 0.26 | GBP |
| 2015 | Hikma Pharmaceuticals PLCShs | 0.96 | 0.22 | GBP |
Gewinn je Aktie- Hikma Pharmaceuticals PLCShs
| 1.3 24 | 0.7 23 | 0.7 22 | 1.3 21 | 1.4 20 | 1.6 19 | 0.9 18 |
Umsatz je Aktie- Hikma Pharmaceuticals PLCShs
| 10.9 24 | 10.4 23 | 9.1 22 | 8.0 21 | 7.7 20 | 7.1 19 | 6.4 18 |
KGV- Hikma Pharmaceuticals PLCShs
| 15.7 24 | 25.8 23 | 22.8 22 | 16.7 21 | 17.7 20 | 12.6 19 | 19.6 18 |
Hikma Pharmaceuticals PLCShs: Die Aktie (in GBP)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (berichtet) | 1.27 | 0.69 | 0.68 | 1.33 | 1.42 | 1.57 | 0.88 |
| Gewinn je Aktie (unverwässert) | 1.27 | 0.69 | 0.68 | 1.33 | 1.42 | 1.57 | 0.88 |
| Gewinn je Aktie (verwässert) | 1.26 | 0.69 | 0.68 | 1.31 | 1.41 | 1.57 | 0.87 |
| Dividende je Aktie | 0.63 | 0.57 | 0.45 | 0.41 | 0.37 | 0.37 | 0.29 |
| Veränderung Dividende je Aktie in % | 11.08 | 25.10 | 11.88 | 10.84 | -1.56 | 27.12 | 16.78 |
| Gesamtdividendenausschüttung in Mio. | 136.95 | 110.21 | 101.48 | 87.25 | 85.00 | 76.03 | 63.00 |
Hikma Pharmaceuticals PLCShs: Unternehmenskennzahlen (in GBP)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 10.95 | 10.40 | 9.08 | 7.97 | 7.67 | 7.11 | 6.43 |
| KGV (Jahresendkurs, Gewinn unverwässert) | 15.70 | 25.85 | 22.78 | 16.74 | 17.68 | 12.65 | 19.56 |
| KGV (Jahresendkurs, Gewinn verwässert) | 15.85 | 26.03 | 22.88 | 16.89 | 17.83 | 12.70 | 19.64 |
| Dividendenrendite Jahresende in % | 3.16 | 3.17 | 2.92 | 1.83 | 1.45 | 1.87 | 1.70 |
| Eigenkapitalquote in % | 45.22 | 47.20 | 48.04 | 56.43 | 51.95 | 54.17 | 48.53 |
| Fremdkapitalquote in % | 54.78 | 52.80 | 51.96 | 43.57 | 48.05 | 45.83 | 51.47 |
Hikma Pharmaceuticals PLCShs: GuV (in Mio. GBP)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 2’447.15 | 2’312.86 | 2’043.38 | 1’856.32 | 1’825.55 | 1’726.84 | 1’556.92 |
| Umsatzveränderung in % | 5.81 | 13.19 | 10.08 | 1.69 | 5.72 | 10.91 | 3.57 |
| Bruttoergebnis vom Umsatz | 1’035.36 | 1’074.77 | 952.28 | 877.62 | 892.11 | 857.54 | 764.21 |
| Bruttoergebnisveränderung in % | -3.67 | 12.86 | 8.51 | -1.62 | 4.03 | 12.21 | 6.40 |
| Operatives Ergebnis | 476.60 | 395.00 | 410.79 | 434.09 | 435.14 | 377.82 | 318.73 |
| Veränderung Operatives Ergebnis in % | 20.66 | -3.84 | -5.37 | -0.24 | 15.17 | 18.54 | 27.08 |
| Ergebnis vor Steuern | 356.08 | 226.06 | 189.16 | 394.82 | 435.14 | 384.87 | 219.74 |
| Veränderung Ergebnis vor Steuern in % | 57.52 | 19.51 | -52.09 | -9.26 | 13.06 | 75.15 | - |
| Ergebnis nach Steuer | 280.95 | 152.85 | 152.62 | 306.11 | 336.10 | 380.96 | 211.49 |
| Veränderung Ergebnis nach Steuer in % | 83.81 | 0.15 | -50.14 | -8.92 | -11.77 | 80.13 | - |
Hikma Pharmaceuticals PLCShs: Bilanz (in Mio. GBP)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Fremdkapital | 2’245 | 1’938 | 1’931 | 1’406 | 1’454 | 1’360 | 1’413 |
| Langzeit Gesamtverbindlichk. je Aktie | 3.00 | 4.02 | 4.70 | 2.84 | 3.04 | 1.03 | 2.95 |
| Eigenkapital | 1’853 | 1’733 | 1’786 | 1’821 | 1’571 | 1’607 | 1’332 |
| Veränderung Eigenkapital in % | 6.98 | -2.86 | -2.00 | 15.95 | -2.26 | 20.79 | 18.21 |
| Bilanzsumme | 4’099 | 3’671 | 3’717 | 3’228 | 3’025 | 2’967 | 2’746 |
| Veränderung Bilanzsumme in % | 11.64 | -1.23 | 15.15 | 6.71 | 1.97 | 8.04 | 9.63 |
Hikma Pharmaceuticals PLCShs: Sonstige Angaben (in GBP)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 1.27 | 0.69 | 0.68 | 1.33 | 1.42 | 1.57 | 0.88 |
| Veränderung Gewinn je Aktie (unverwässert) in % | 83.40 | 1.57 | -48.58 | -6.95 | -9.53 | 79.40 | - |
| Gewinn je Aktie (verwässert) | 1.26 | 0.69 | 0.68 | 1.31 | 1.41 | 1.57 | 0.87 |
| Veränderung Gewinn je Aktie (verwässert) in % | 82.88 | 1.34 | -48.37 | -6.97 | -9.92 | 79.39 | - |
| Anzahl Mitarbeiter | - | 9’100 | 8’800 | 8’700 | 8’600 | 8’600 | 8’400 |
| Veränderung Anzahl Mitarbeiter in % | - | 3.41 | 1.15 | 1.16 | 0.00 | 2.38 | - |
Hikma Pharmaceuticals PLCShs Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Hikma Pharmaceuticals PLCShs | Quartalszahlen | 08.08.2025 |
| Hikma Pharmaceuticals PLCShs | Quartalszahlen | 19.02.2026 |
| Hikma Pharmaceuticals PLCShs | Quartalszahlen | 30.07.2026 |
| Hikma Pharmaceuticals PLCShs | Quartalszahlen | 25.02.2027 |
Hikma Pharmaceuticals PLCShs vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q4 2024 Earnings Release | 26.02.2025 |
| Quartalszahlen | Q2 2024 Earnings Release | 08.08.2024 |
| Hauptversammlung | Annual General Meeting | 25.04.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 22.02.2024 |
| Quartalszahlen | Q2 2023 Earnings Release | 03.08.2023 |
| Hauptversammlung | Annual General Meeting | 28.04.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 23.02.2023 |
| Quartalszahlen | Q2 2022 Earnings Release | 04.08.2022 |
| Hauptversammlung | Annual General Meeting | 25.04.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 24.02.2022 |
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 8’400 | 8’600 | 8’600 | 8’700 | 8’800 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.19 | 0.20 | 0.21 | 0.21 | 0.23 |
Bilanz (in Mio. GBP) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 1’310 | 1’395 | 1’406 | 1’546 | 1’662 |
| Summe Anlagevermögen | 1’436 | 1’572 | 1’619 | 1’682 | 2’055 |
| Summe Aktiva | 2’746 | 2’967 | 3’025 | 3’228 | 3’717 |
Bilanz (in Mio. GBP) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 1’413 | 1’360 | 1’454 | 1’406 | 1’931 |
| Summe Eigenkapital | 1’332 | 1’607 | 1’571 | 1’821 | 1’786 |
| Summe Passiva | 2’746 | 2’967 | 3’025 | 3’228 | 3’717 |
Adresse
| 1 New Burlington Place, W1S 2HR London | |
| Telefon | +44 (20) 7399-2760 |
| Fax | +44 (20) 7399-2761 |
| URL | http://www.hikma.com |
Management
|
Bassam Wael Rushdi Kanaan
Executive Vice President-Corporate Development |
|
Cynthia L. Flowers
Independent Non-Executive Director |
|
Deneen Vojta
Independent Non-Executive Director |
|
Douglas Malcolm Hurt
Independent Non-Executive Director |
|
Hafrun Fridriksdottir
President-Generics Business |
|
Helen Middlemist
Group Secretary |
|
Hill Julie
SVP-Corporate Quality Compliance, Health & Safety |
|
Hussein Arkhagha
Chief People Officer |
|
John J. Castellani
Independent Non-Executive Director |
|
Khalid Walid Hosni Nabilsi
Chief Financial Officer |
|
Kristy Ronco
Executive VP-Sales & Marketing |
|
Laura Mihaela Balan
Independent Non-Executive Director |
|
Majda Labadi
Executive VP-Organizational Development |
|
Mary Regina Henderson
Independent Non-Executive Director |
|
Mohammed Ali Khaldoun Al-Husry
Non-Executive Director |
|
Riad Mishlawi
Chief Executive Officer & Director |
|
Said Samih Taleb Darwazah
Executive Chairman |
|
Susan Ringdal
Executive VP-Strategic Planning & Global Affairs |
|
Victoria Mary Hull
Senior Independent Non-Executive Director |
|
William C. Larkins
President-Injectables Business |